EXECUTIVE SUMMARY

The healthcare sector is large, complex and growing at a faster rate than GDP in every major economy.\(^1\) Purely on the basis of changing demographics, the sector is expected to be larger in five, ten and twenty years.\(^2\) Despite this growth potential, most institutional investors do not think about their exposure to healthcare in the same way they may think about their exposure to other sectors such as real estate or energy. We believe healthcare merits the same consideration those other sectors receive. We find that healthcare exposure in many investors' portfolios is much smaller than the sector’s expenditures in the overall economy. We believe that adjusting this relative under-allocation to healthcare can provide investors with additional exposure to a large and rapidly growing sector with an attractive risk/return profile. Additionally, certain healthcare investment strategies may generate significant current income which may be especially attractive to institutional investors.

BACKGROUND

It is difficult to open the newspaper without seeing articles on the healthcare sector. Top stories may include promising new medical therapies for hard-to-treat diseases, budget discussions about the impact of rising healthcare costs on government solvency, announcements of multi-billion dollar biotech company acquisitions and debates over the Affordable Care Act (ACA), better known as “Obama Care.”

---


\(^{2}\) Sources: Centers for Medicare & Medicaid Services, 2012; International Monetary Fund, 2012.
Demographic trends in developed countries virtually ensure that healthcare spending will increase.

Figure 1 shows that U.S. healthcare sector spending is massive, accounting for $9,250 per person in 2013 and spending is expected to grow at an increasing pace.

Figure 1: U.S. Healthcare Spending Per Person

This massive spending is likely to increase for several reasons. For starters, demographic trends in developed countries virtually ensure that healthcare spending will increase. Age is one of the most significant variables in healthcare consumption. As Figure 2 shows, spending on Medicare beneficiaries in the U.S. (individuals over 65 years of age) is much higher than healthcare spending on younger populations. In the future, this older age group will represent an increasing portion of the overall population, pushing overall healthcare costs higher.

Figure 2: Current Healthcare Spending by Age Group in the U.S.
A significant portion of the healthcare sector is not open to direct investment.

### Figure 3: Healthcare Composition of Public Market Indices

<table>
<thead>
<tr>
<th>Country Exchange Ticker</th>
<th>Brazil BOVESPA</th>
<th>India BSE Sensex</th>
<th>Russia RTS</th>
<th>China SSE</th>
<th>Frontier Markets MSCI</th>
<th>U.S. S&amp;P 500</th>
<th>Europe MSCI EU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consumer</td>
<td>21%</td>
<td>12%</td>
<td>3%</td>
<td>4%</td>
<td>9%</td>
<td>23%</td>
<td>25%</td>
</tr>
<tr>
<td>Energy &amp; Utilities</td>
<td>28%</td>
<td>30%</td>
<td>60%</td>
<td>24%</td>
<td>9%</td>
<td>14%</td>
<td>14%</td>
</tr>
<tr>
<td>Financial</td>
<td>22%</td>
<td>18%</td>
<td>21%</td>
<td>56%</td>
<td>51%</td>
<td>16%</td>
<td>20%</td>
</tr>
<tr>
<td>Healthcare</td>
<td>-</td>
<td>4%</td>
<td>-</td>
<td>1%</td>
<td>2%</td>
<td>12%</td>
<td>13%</td>
</tr>
<tr>
<td>Industrial</td>
<td>4%</td>
<td>12%</td>
<td>1%</td>
<td>10%</td>
<td>10%</td>
<td>10%</td>
<td>11%</td>
</tr>
<tr>
<td>Information Technology</td>
<td>1%</td>
<td>16%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19%</td>
<td>3%</td>
</tr>
<tr>
<td>Materials</td>
<td>20%</td>
<td>4%</td>
<td>11%</td>
<td>4%</td>
<td>4%</td>
<td>3%</td>
<td>9%</td>
</tr>
<tr>
<td>Telecom</td>
<td>4%</td>
<td>4%</td>
<td>4%</td>
<td>1%</td>
<td>15%</td>
<td>3%</td>
<td>6%</td>
</tr>
</tbody>
</table>

Source: Capital IQ, 2013

The U.S. healthcare sector represents only approximately 12 percent of public equity indices versus 18 percent of U.S. GDP, as shown in Figure 4. One reason for this is that not-for-profit organizations are major players in the healthcare sector. For example, hospital services count for more than 25 percent of the healthcare sector and 80 percent of those hospitals are not-for-profit or government-owned. This means that a significant portion of the healthcare sector is not open to direct investment.

### Figure 4: Healthcare Spending Compared to GDP

<table>
<thead>
<tr>
<th>Country</th>
<th>GDP ($bn)</th>
<th>% of GDP</th>
<th>GDP Growth</th>
<th>HC Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>$2,708</td>
<td>18%</td>
<td>3%</td>
<td>6%</td>
</tr>
<tr>
<td>European Union</td>
<td>$1,569</td>
<td>10%</td>
<td>2%</td>
<td>7%</td>
</tr>
<tr>
<td>Japan</td>
<td>$424</td>
<td>8%</td>
<td>1%</td>
<td>3%</td>
</tr>
<tr>
<td>BRICs</td>
<td>$607</td>
<td>5%</td>
<td>7%</td>
<td>13%</td>
</tr>
<tr>
<td>Brazil</td>
<td>$188</td>
<td>9%</td>
<td>4%</td>
<td>12%</td>
</tr>
<tr>
<td>Russia</td>
<td>$80</td>
<td>5%</td>
<td>4%</td>
<td>14%</td>
</tr>
<tr>
<td>India</td>
<td>$69</td>
<td>4%</td>
<td>8%</td>
<td>11%</td>
</tr>
<tr>
<td>China</td>
<td>$270</td>
<td>5%</td>
<td>9%</td>
<td>13%</td>
</tr>
</tbody>
</table>

Healthcare private capital investment strategies fall into three main categories.

HEALTHCARE PRIVATE CAPITAL

The earliest funds that invested in healthcare tended to be multi-sector in focus with one or a few investment professionals focused on healthcare investments. Over the last 20 years, more dedicated firms have been created, due in part to recognition that investing in this sector requires a lot of expertise. In addition to many healthcare-focused firms, many generalist firms continue to devote portions of their investment vehicles to healthcare opportunities. There are over 305 managers in the U.S. who focus on healthcare and several hundred more that identify healthcare as a sector of interest.

Healthcare private capital investment strategies fall into three main categories: venture capital, private equity and royalties and structured credit. Each category may be attractive or unattractive at a given point in time and we opportunistically invest based on our views of capital scarcity or excess as well as the attractiveness of specific opportunities. We currently believe that attractive investment opportunities in healthcare can best be accessed through private equity and royalties and structured credit strategies.

Venture Capital

The majority of investment managers who target healthcare do so through venture capital investment strategies. In fact, venture capital is the strategy that comes to mind for most limited partners when they think about the healthcare sector. This strategy focuses on research and development (R&D) stage companies (seed, early, middle or late stage development) with potential breakthrough technologies. These companies typically have negative cash flow and are funded by syndicates of venture and corporate investors who hope to sell or IPO the companies after establishing proof of concept for the new technology.

As shown in Figure 5, healthcare venture capital returns have historically been lower and more volatile than healthcare private equity returns. During the previous decade, too much capital created too many companies seeking too few exits. As a consequence of poor returns and general skepticism among limited partners, many managers have struggled to raise funds. In our opinion, the outlook for healthcare venture capital remains challenging.

Figure 5: Healthcare Returns Over Time – Private Equity vs. Venture Capital

![Figure 5: Healthcare Returns Over Time – Private Equity vs. Venture Capital](source: Cambridge Associates, 2013. Returns are aggregated at the deal level.)

4 Source: Siguler Guff estimates as of December 31, 2013.
Private Equity

Healthcare private equity is a strategy that targets investments in commercial-stage healthcare companies. We estimate that there are as many as 50,000 commercial-stage healthcare companies in the U.S. These include a wide array of businesses such as service providers (e.g., clinics, for-profit hospitals and surgery centers), product companies (e.g., pharmaceuticals, devices and equipment), contract research, product distribution, insurance and outsourced business services. As shown in Figure 6, we estimate that there are over 60 different sub-sectors in the healthcare industry (shading represents sectors that we believe are attractive).

The healthcare sector not only contains a wide variety of business types, we find that these companies tend to be widely dispersed throughout the U.S. This is because companies that provide healthcare services are needed in approximate proportion to population sizes. The healthcare sector is large, complex and fragmented in terms of business types, business sizes and geographic dispersion, perhaps even more so than other industries. We believe these characteristics create structural inefficiencies in deal sourcing and pricing that present the potential to earn attractive returns. We estimate there are more than 50 managers dedicated to healthcare private equity and several hundred more who invest in the healthcare sector through non-dedicated investment vehicles. We find that managers tend to concentrate on specific sub-sectors of the market in order to increase their knowledge and enhance their deal flow.

Figure 6: Healthcare Sub-Sectors

![Figure 6: Healthcare Sub-Sectors](source: Siguler Guff)

Risk-adjusted IRR, created by analyzing sector returns versus sector volatility, is another interesting statistic. Figure 7 shows that healthcare has the highest level of return per increment of risk. We believe that these historical returns are telling in that they show that healthcare private equity has been a good correlate for the overall growth and low volatility of the healthcare sector.
Healthcare private equity will continue to be an attractive investment area for several reasons.

We believe that healthcare private equity will continue to be an attractive investment area for several reasons. First, we believe that the healthcare sector will continue to grow as suggested by the demographic drivers referred to earlier. Second, we believe that commercial healthcare companies are well-positioned to capture this growth because their revenue increases will be closely correlated with increased spending. Lastly, there are so many healthcare businesses, especially at the small end of the market, that there tends to be inefficiencies in pricing, which we believe can be exploited by private equity.

**Royalties and Structured Credit**

The royalties and structured credit strategy is another approach to investing in healthcare. Royalties are contracts to receive payments based on the sales of products in return for use of the intellectual property that underlies those products. Royalty agreements are created when intellectual property rights are transferred between individuals, academic institutions and companies. Related to drug and biotechnology royalties is an adjacent space that we refer to as healthcare structured credit, which includes loans, typically senior, backed by revenue-generating product assets. These loans usually bear high coupons and contain equity incentives such as warrants. Often these loans have liens against intellectual property, including patents, regulatory filings and other assets as collateral. Royalties have features of both fixed income and equity investments. The cash flows are immediate, but they vary based on actual sales of the product.

The royalty market has expanded considerably over the last 20 years due to growth in the drug and biotechnology industries and increases in the number of royalty contracts. We estimate that there is an addressable royalty market in the U.S. of approximately $65 billion. Royalty agreements are created when intellectual property rights are transferred between individuals, academic institutions and companies. Related to drug and biotechnology royalties is an adjacent space that we refer to as healthcare structured credit, which includes loans, typically senior, backed by revenue-generating product assets. These loans usually bear high coupons and contain equity incentives such as warrants. Often these loans have liens against intellectual property, including patents, regulatory filings and other assets as collateral. Royalties have features of both fixed income and equity investments. The cash flows are immediate, but they vary based on actual sales of the product.

5 Capital Royalty deal list, L.E.K. analysis.
We believe that the royalties and structured credit strategy is interesting, but we have observed firsthand some of the challenges that it poses. The attractive features of the strategy are that investors are able to avoid development risks and capture senior cash flows from high margin healthcare product assets. We believe that the best approach to this strategy is to participate opportunistically and outside of traditional private equity fund structures.

SUMMARY AND OUTLOOK
The healthcare sector is large, complex and seems to be growing faster and with less volatility than other sectors. The sector’s high growth and low cyclical nature make it attractive to investors. There are a number of strategies investors can use to access the healthcare sector. Ideally, investors could develop approaches which capture the good market return ($\beta$) and add excess return ($\alpha$) by flexibly allocating to the right strategies, sub-sectors and deals within the sector.

Achieving the best allocation to healthcare poses challenges. There are several strategies to consider and one must also take into account many variables that shape the sector such as policy, technology and reimbursement to name a few. Successfully navigating this landscape requires significant sector expertise. In addition, the numerous opportunities tend to be widely dispersed, which means that sourcing potential investments can pose challenges.

We find that the best approach is to pursue healthcare private equity and royalties and structured credit strategies that focus on commercial-stage investment opportunities. Within these strategies, we feel that the best investment approach is one that incorporates a significant knowledge base and experience in the healthcare sector, broad sourcing capabilities, and a strong view on the types of opportunities that are attractive given the sector’s rapid evolution and growth.

CERTAIN DISCLOSURES
This article is for informational purposes only and is not an offer, solicitation or recommendation to purchase or sell any securities or partnership interests of any investment fund managed by or affiliated with Siguler Guff Advisers, LLC (“SGA”), (each, a “Fund” and collectively, the “Funds”). Each Fund is offered or sold pursuant to a Fund’s Private Placement Memorandum and related documents (such as an Agreement of Limited Partnership) that set forth detailed information regarding such Fund, including investment program and restrictions, management fees and expenses, investment risks and conflicts of interest.

This article does not present a full or balanced description of the real estate market generally, and should not be used as the exclusive basis for an investment decision. Any reproduction or distribution of this article, or any information contained herein, is prohibited. This Presentation may contain performance information. Past performance does not guarantee future results, and no representation or warranty, express or implied, is made regarding future performance. This article contains certain statements, estimates and projections that are “forward-looking statements.” All statements other than statements of historical fact in this Presentation are forward-looking statements and include statements and assumptions relating to the following: plans and objectives of management for future operations or economic performance; conclusions and projections about current and future economic and political trends and conditions; and projected financial results and results of operations. These statements can generally be identified by the use of forward-looking terminology, including “may,” “believe,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “rankings” or other similar words. Siguler Guff does not make any representations or warranties (express or implied) about the accuracy of such forward-looking statements. Readers are cautioned that actual results of an investment could differ materially from forward-looking statements or the prior or projected results of the Funds. Readers of this article are cautioned not to place undue reliance on forward-looking statements.

This Presentation may include footnotes or endnotes which, if included, are an integral part of this Presentation and should be read in their entirety. Any sale of securities in Canada will be affected through an affiliated broker dealer.

Interests in the Funds are offered through Siguler Guff Global Markets, LLC (“SGGM”), a registered broker dealer and FINRA member. SGGM is an affiliate of SGA and the Funds, and representatives of SGGM may also be employees of SGA (or its direct or indirect parent). To the extent that certain registered representatives of SGGM are compensated based on their marketing efforts, these representatives’ relationship with the Funds and SGA may conflict with the interests of investors.
BNY Mellon Investment Management is one of the world's leading investment management organizations and one of the top U.S. wealth managers, encompassing BNY Mellon's affiliated investment management firms, wealth management organization and global distribution companies. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may also be co-used as a generic term to reference the Corporation as a whole or its various subsidiaries generally. • The statements and opinions expressed in this document are those of the authors as of the date of the article, are subject to change as economic and market conditions dictate, and do not necessarily represent the views of BNY Mellon, BNY Mellon Investment Management EMEA Limited or any of their respective affiliates. The information contained in this document has been provided as a general market commentary only, and does not constitute legal, tax, accounting, or professional counsel or investment advice, is not predictive of future performance, and should not be construed as an offer to sell or a solicitation to buy any security or make an offer where otherwise required by law without taking into account the investment objective, financial situation or needs of any particular person. BNY Mellon Investment Management EMEA Limited and its affiliates are not responsible for any subsequent investment advice given based on the information supplied. This document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. To the extent that these materials contain statements about future performance, such statements are forward looking and are subject to a number of risks and uncertainties. Information and opinions presented in this material have been obtained or derived from sources which BNY Mellon believed to be reliable, but BNY Mellon makes no representation to its accuracy and completeness. BNY Mellon accepts no liability for loss arising from use of this material. If nothing is indicated to the contrary, all figures are unaudited.

Past performance is not a guide to future performance. The value of investments and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment you may get back less than you originally invested. • While the information in this document is not intended to be investment advice, it may be deemed a financial promotion in non-U.S. jurisdictions. Accordingly, where this document is used or distributed in any non-U.S. jurisdiction, the information provided is for use by professional and wholesale investors only and not for onward distribution to, or to be relied upon by, retail investors. • This document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country in which such distribution or use would be contrary to local law or regulation. This document may not be distributed or used for the purpose of offers or solicitations in an jurisdiction in which such offers or solicitations are unlawful or not authorized, or where there would be, by virtue of such distribution, new or additional registration requirements. Persons into whose possession this document comes are required to inform themselves about and to observe any restrictions that apply to the distribution of this document in their jurisdiction. The investment products and services mentioned here are not insured by the FDIC (or any other state or federal agency), are not deposits or of guaranteed by any bank, and may lose value. This document should not be published in hard copy, electronic form, via the web or in any other medium accessible to the public, unless authorized by BNY Mellon Investment Management EMEA Limited.

In Australia, this document is issued by BNY Mellon Investment Management Australia Ltd (ABN 56 102 482 815, AFSL License No. 227865). Authorized and regulated by the Australian Securities & Investments Commission. • In Brazil, this document is issued by BNY Mellon Serviços Financeiros DTVM S.A., Av. Presidente Wilson, 231, 11th floor, Rio de Janeiro, RJ, Brazil, CEP 20030-905. BNY Mellon Serviços Financeiros DTVM S.A. is a Financial Institution, duly authorized by the Brazilian Central Bank to provide securities distribution and by the Brazilian Securities and Exchange Commission (CVM) to provide securities portfolio managing services under Declaratory Act No. 4.620, issued on December 19, 1997. • Securities in Canada are offered through BNY Mellon Asset Management Canada Ltd., registered as a Portfolio Manager and Exempt Market Dealer in all provinces and territories of Canada, and an Investment Fund Manager and Commodity Trading Manager in Ontario. • In Dubai, United Arab Emirates, this document is issued by the Dubai branch of the regulated by the Dubai Financial Services Authority. This material is intended for Professional Clients only and no other person should act upon it. • In Hong Kong, this document is issued by BNY Mellon Investment Management Hong Kong Limited. Regulated by the Hong Kong Securities and Futures Commission. • In Japan, this document is issued by BNY Mellon Asset Management Japan Limited. BNY Mellon Asset Management Japan Limited is a Financial Instruments Business Operator with license no 406 (Kinsho) at the Commissioner of Kanto Local Finance Bureau and is a Member of the Investment Trusts Association, Japan and Japan Securities Investment Advisers Association. • In Singapore, this document is issued by BNY Mellon Investment Management Singapore Pte. Ltd., Limited Co. Reg. 201220427E. Regulated by the Monetary Authority of Singapore. • This document is issued in the UK and in mainland Europe, by BNY Mellon Investment Management EMEA Limited, 160 Queen Victoria Street, London EC4V 4LA. Registered in England No. 1118580. Authorized and regulated by the Financial Conduct Authority. • This document is issued in the United States by BNY Mellon Investment Management.

By signing the signature block, the undersigned acknowledges that BNY Mellon does not provide investment advice, it may be deemed a financial promotion in non-U.S. jurisdictions and to the extent that these materials contain statements about future performance, such statements are forward looking and are subject to a number of risks and uncertainties. Information and opinions presented in this material have been obtained or derived from sources which BNY Mellon believed to be reliable, but BNY Mellon makes no representation to its accuracy and completeness.

©2014 The Bank of New York Mellon Corporation. 03/14